Srdan Verstovsek, MD
M.D. Anderson Cancer Center · UT MD Anderson Cancer Center · MDACC
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Srdan Verstovsek, MD as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-12 08:28 UTC. Open this list on ClinicalTrials.gov
- Ph2NCT02267278 · Ruxolitinib and Pracinostat Combination Therapy for Patients With Myelofibrosis (MF)M.D. Anderson Cancer Center · completed · Myeloproliferative Diseases · principal investigator
- Ph2NCT01375140 · Ruxolitinib and Lenalidomide for Patients With MyelofibrosisM.D. Anderson Cancer Center · completed · Myeloproliferative Diseases · principal investigator
- Ph2NCT01340651 · Study of Ruxolitinib (INCB018424) Sustained Release Formulation in Myelofibrosis PatientsIncyte Corporation · completed · Myelofibrosis · principal investigator
- Ph1/Ph2NCT01251965 · Phase l/II Study of Ruxolitinib for Acute LeukemiaM.D. Anderson Cancer Center · terminated · Leukemia · principal investigator
- Ph3NCT01243944 · Study of Efficacy and Safety in Polycythemia Vera Subjects Who Are Resistant to or Intolerant of Hydroxyurea: JAK Inhibitor INC424 (INCB018424) Tablets Versus Best Available Care: (The RESPONSE Trial)Incyte Corporation · completed · Polycythemia Vera · study director
- Ph3NCT00952289 · COntrolled MyeloFibrosis Study With ORal JAK Inhibitor Treatment: The COMFORT-I TrialIncyte Corporation · completed · MPN (Myeloproliferative Neoplasms) · study director
- Ph2NCT00946270 · Pomalidomide for Myelofibrosis PatientsM.D. Anderson Cancer Center · completed · Polycythemia Vera, Thrombocythemia · principal investigator
- Ph2NCT00918931 · Obatoclax for Systemic MastocytosisM.D. Anderson Cancer Center · terminated · Leukemia, Systemic Mastocytosis · study chair
- Ph1NCT00910728 · Study to Assess the Safety of AZD1480 in Patients With Myeloproliferative DiseasesAstraZeneca · completed · Primary Myelofibrosis (PMF), Post-Polycythaemia Vera, Essential Thrombocythaemia Myelofibrosis · principal investigator
- Ph1/Ph2NCT00509899 · Open Label Ruxolitinib (INCB018424) in Patients With Myelofibrosis and Post Polycythemia Vera/Essential Thrombocythemia MyelofibrosisIncyte Corporation · completed · Myelofibrosis, Polycythemia Vera, Thrombocytosis · principal investigator
- Ph2NCT00493129 · Ontak (Denileukin Diftitox) in Patients With Systemic Mastocytosis (SM)M.D. Anderson Cancer Center · completed · Leukemia, Systemic Mastocytosis · principal investigator
- Ph2NCT00449748 · Everolimus (RAD001) as Therapy for Patients With Systemic MastocytosisM.D. Anderson Cancer Center · completed · Systemic Mastocytosis · principal investigator
- Ph2NCT00352794 · Lenalidomide for Patients With Myelofibrosis (MF)M.D. Anderson Cancer Center · completed · Myelofibrosis · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-12 08:28 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. Coverage is US federal funding only; UK and EU funders are not searched yet.
No NIH project could be tied to this name by a shared trial or a matching institution.
Most cited trial papers
PubMed returned no clinical-trial papers for this author name.